Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

This publication has 78 references indexed in Scilit:

• Prevalence of Overweight and Obesity in the United States, 1999-2004
  JAMA, 2006
• Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
  Behavioural Pharmacology, 2005
• Efficacy and Safety of Topiramate in the Treatment of Obese Subjects With Essential Hypertension
  The American Journal of Cardiology, 2005
• Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment
  International Journal of Neuropsychopharmacology, 2005
• Long-term weight loss after diet and exercise: a systematic review
  International Journal of Obesity, 2005
• A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine
  Brain Research, 2004
• Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims
  Molecular Psychiatry, 2004
• Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
  New England Journal of Medicine, 1999
• A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity
  Clinical Therapeutics, 1996
• The Hospital Anxiety and Depression Scale
  Acta Psychiatrica Scandinavica, 1983